Evidence map›Paper›PMID 31308935›Full record

ArticleTherapeutic advances in psychopharmacology2019

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal

Marjie L Hard, Angela Wehr, Lisa von Moltke, Yangchun Du, Sarah Farwick, David P Walling, John Sonnenberg

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. New Antipsychotic Medications in the Last Decade.Current psychiatry reports · 2021
    Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Marjie L HardAlkermes, Inc., Waltham, MA, USA.
Angela WehrAlkermes, Inc., Waltham, MA, USA.
Lisa von MoltkeAlkermes, Inc., Waltham, MA, USA.
Yangchun DuAlkermes, Inc., Waltham, MA, USA.
Sarah FarwickUptown Research Institute, Chicago, IL, USA.
John SonnenbergUptown Research Institute, Chicago, IL, USA.
Alkermes (United States) · USModerna Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21 days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a single injection of a NanoCrystal

methodsPatients with schizophrenia or schizoaffective disorder (

resultsPlasma aripiprazole concentrations after a single AL

conclusionAL

Indexed as

ALNCDantipsychoticaripiprazolearipiprazole lauroxilbioavailabilityinitiation regimeninjection sitelong-acting injectablepharmacokineticssafety/tolerability

Identifiers

PMID31308935
PMCPMC6607563
OpenAlexW2953606468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.